|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-6-22
|
|
pubmed:abstractText |
The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patients enrolled on two recently reported clinical trials.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-11331473,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-11462942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-12963650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-1359851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-15028824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-15197014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-16175188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-16418882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-16782929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-17227978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-17324767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-17418869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-17592291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18249033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18281668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18538501,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18640929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18640930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18640931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18640932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-18781364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-19029412,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-19092346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-19194760,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-3308077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-4015380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20162463-8873528
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1534-4681
|
|
pubmed:author |
pubmed-author:AbbruzzeseJames LJL,
pubmed-author:AbdallaEddie KEK,
pubmed-author:CraneChristopher HCH,
pubmed-author:EvansDouglas BDB,
pubmed-author:FlemingJason BJB,
pubmed-author:KatzMatthew H GMH,
pubmed-author:LeeJeffrey EJE,
pubmed-author:LeeJeffrey HJH,
pubmed-author:PistersPeter W TPW,
pubmed-author:SunCharlotte CCC,
pubmed-author:TammEric PEP,
pubmed-author:VaradhacharyGauri RGR,
pubmed-author:VautheyJean-NicolasJN,
pubmed-author:WangHuaminH,
pubmed-author:WolffRobert ARA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1794-801
|
|
pubmed:dateRevised |
2010-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20162463-Adenocarcinoma,
pubmed-meshheading:20162463-Adult,
pubmed-meshheading:20162463-Aged,
pubmed-meshheading:20162463-Aged, 80 and over,
pubmed-meshheading:20162463-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20162463-CA-19-9 Antigen,
pubmed-meshheading:20162463-Combined Modality Therapy,
pubmed-meshheading:20162463-Female,
pubmed-meshheading:20162463-Humans,
pubmed-meshheading:20162463-Male,
pubmed-meshheading:20162463-Middle Aged,
pubmed-meshheading:20162463-Neoadjuvant Therapy,
pubmed-meshheading:20162463-Pancreatic Neoplasms,
pubmed-meshheading:20162463-Pancreaticoduodenectomy,
pubmed-meshheading:20162463-Radiotherapy, Adjuvant,
pubmed-meshheading:20162463-Radiotherapy Dosage,
pubmed-meshheading:20162463-Retrospective Studies,
pubmed-meshheading:20162463-Survival Rate,
pubmed-meshheading:20162463-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
|
|
pubmed:affiliation |
Department of Surgery, The University of California, Orange, CA, USA. katzmh@uci.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
